# KLOW Peptide Dosage Research — Vial Composition and Component Protocols > KLOW peptide dosage context: the 80 mg canonical vial composition, component half-lives, research routes, and the pharmacokinetic mismatch — no human dosing recommendations. ## The numbers, plainly KLOW peptide is sold as a research vial, not a clinical product, so there is no approved dose. What exists is a canonical vial composition — the most widely referenced research-handling specification — and the dose ranges from each component's published studies. These are not recommendations; they are the data points the research generated. The four components clear the body at very different speeds, which means a single co-formulated vial does not deliver all four at matched exposures. That pharmacokinetic mismatch is the first fact the dosage record requires. ## KLOW peptide dosage: the canonical vial The most widely cited KLOW research-vial composition is 80 mg total: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg. GHK-Cu is the mass-dominant component at approximately 62.5% by weight — the broadest band of the aurora in the vial. No validated human dosing exists for the blend. Component-level research doses differ widely by species and route and are not additive into a single 'KLOW dose.' The 80 mg composition is a research-handling specification, not a therapeutic label. The vial is lyophilized (freeze-dried) for stability and is typically reconstituted with bacteriostatic water (water preserved with a small amount of benzyl alcohol to prevent bacterial growth) for laboratory handling. GHK-Cu carries a chelated copper(II) ion that can participate in redox chemistry (electron-transfer reactions) when co-dissolved with the other peptides — a theoretical compatibility consideration that has not been formally characterized for this mixture. ## KLOW dosage: the pharmacokinetic mismatch The four peptides have markedly different reported half-lives — a pharmacokinetic mismatch (when co-formulated compounds have very different absorption and clearance rates, so a single dose cannot keep all components at matched exposures in the target tissue) is inherent in the blend. BPC-157 formal PK: Wang et al. (2022) in *Frontiers in Pharmacology* is the first rigorous ADME study [11]. Elimination half-life under 30 minutes in rats and dogs. Intramuscular bioavailability approximately 14-19% in rats and 45-51% in dogs. Metabolism produces small peptide fragments entering normal amino-acid metabolism. Excretion via urine and bile. Linear pharmacokinetics across the tested dose range. KPV and GHK-Cu are tripeptides — three amino acids each — and clear at least as fast as BPC-157, likely faster. No formal PK study on KPV or GHK-Cu administered systemically is in the public literature at comparable detail. The PepT1 substrate Km for KPV is approximately 160 micromolar, which describes intestinal uptake rate, not systemic clearance [3]. TB-500 (the short Ac-LKKTETQ heptapeptide fragment) has not been formally characterized in the same manner as native thymosin beta-4. The native 43-amino-acid protein has a different PK profile from the short fragment, and available data for the fragment are limited. The consequence: the four lights do not stay lit at the same time after a single administration. This is the honest darkness the aurora records. ## KLOW peptide dosage and frequency: component research context The published component research used the following dose ranges — these are what was administered to which species at which dose by which route in the cited studies, not human dosing recommendations. **BPC-157:** In the Staresinic (2003) Achilles tendon study, doses of 10 micrograms, 10 nanograms and 10 picograms per rat intraperitoneally, once daily [9]. In angiogenesis models, dose ranges vary; the Hsieh (2017) VEGFR2 study used cell-culture and in vivo concentrations not directly translatable to a systemic dose [6]. The 2025 IV safety pilot in two humans used 10 mg day 1 and 20 mg day 2 in 250 mL saline as a 1-hour infusion [10] — not an efficacy dose, a safety-tolerance observation. **GHK-Cu:** Low-nanomolar concentrations (1-10 nM) in cell culture for transcriptomic effects [4][5]; topical formulations in clinical cosmetic/wound studies (absolute dose not reported per study). No validated systemic dose in humans. **KPV:** 10 nanomolar (nM) in intestinal epithelial cell culture; 100 micromolar (100 uM) in drinking water for mouse colitis models [3]. No validated systemic human dose. **TB-500 / thymosin beta-4:** The Malinda (1999) wound-healing study used topical and intraperitoneal native thymosin beta-4; as little as 10 picograms stimulated keratinocyte migration in culture [8]. Native protein doses are not directly comparable to the short TB-500 fragment. None of these component doses translates into a KLOW blend dose — the ratios in the research vial (50:10:10:10 mg) were not derived from a dose-optimization study of the blend. There is no validated KLOW dosing protocol in the scientific literature. ## Route and stability considerations Routes studied in the component literature include subcutaneous injection (the primary research-handling route for the blend), topical application (GHK-Cu, KPV), oral and targeted-delivery formulations (KPV, BPC-157), and intravenous infusion (BPC-157, human IV pilot). Intra-articular administration of BPC-157 has also been explored in animal models. Lyophilized stability is favorable for long-term storage of the blend. Reconstituted solution is typically refrigerated and used within a defined period in laboratory settings. GHK-Cu's copper(II) ion is a redox-active species — in theory, co-dissolving it with BPC-157 and the other components could affect peptide oxidation state over time; this has not been formally characterized for the KLOW mixture specifically. Reconstitution protocol for any research application would depend on the specific laboratory context and the purity and source of the material. --- Four lights in one polar sky — a cited editorial record of the component research, the honest gap kept dark.